Hyperfine Swoop® Portable MR Imaging® System Utilized in Multicenter SAFE MRI ECMO Study Published in the September 29th Issue of Circulation

HYPR 10.01.2024

Full Press ReleaseSEC FilingsOur HYPR Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Hyperfine Expands Global Market Reach with New Distribution Partnerships in European and Middle Eastern Markets
  • 12.05.2024 - Hyperfine Announces Extensive Clinical Study Coverage at RSNA 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop® System Across Different Sites of Care
  • 12.03.2024 - Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

Recent Filings

  • 11.18.2024 - 4 Statement of changes in beneficial ownership of securities

The SAFE MRI ECMO study evaluated the use of ultra-low-field portable MR imaging on ICU patients undergoing extracorporeal membrane oxygenation (ECMO) with an elevated risk of acute brain injury (ABI)

GUILFORD, Conn.--(BUSINESS WIRE)--Oct. 1, 2024--Hyperfine, Inc.(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today congratulates investigators atJohns Hopkins Hospitaland theUniversity of Texas-Houstonon the publication of an exciting study using the Swoop® system for patients on extracorporeal membrane oxygenation (ECMO) support.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20241001092541/en/

(Photo: Business Wire)

(Photo: Business Wire)

The study, entitledClinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study,was published in the September issue ofCirculation. The prospective observational study evaluated the safety of using ultra-low-field portable brain MRI on patients in cardiac ICUs undergoing ECMO and investigated the frequency of acute brain injury (ABI).

The use of ECMO has dramatically increased over the past decade but carries an elevated risk of ABI, which substantially increases the risk of mortality. The inability to conduct timely neuroimaging on ECMO patients is a significant barrier to effectively detecting and treating ABI. The study cites, “ultra-low-field portable technology specifically addresses this issue, enabling clinically meaningful, sensitive imaging ... in complex clinical settings, such as intensive care units.”

“We would like to congratulateDr. Choand his collaborators on the publication of this exciting data in such a prestigious journal. This study highlights the value of the Swoop® system in clinical situations where conventional MRI is not accessible,” said Dr.Edmond Knopp, Chief Medical Officer at Hyperfine. “The ability to perform safe, bedside MRI neuroimaging with our ultra-low-field portable system provides clinicians with real-time insights into a patient’s acute brain injury state, potentially improving patient outcomes by enabling earlier interventions in high-risk settings. Hyperfine recommends that institutions ensure the safe use of ECMO systems when used within the Swoop® system’s 5 gauss line.”

For more information about the Swoop® Portable MR Imaging® system, please visithyperfine.io.

About the Swoop® Portable MR Imaging® System

The Swoop® Portable MR Imaging® system isU.S. Food and Drug Administration(FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in theEuropean Unionand UKCA certification in theUnited Kingdom. The Swoop® system is commercially available in a select number of international markets.

AboutHyperfine, Inc.

Hyperfine, Inc.(Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission ofHyperfine, Inc.is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr.Jonathan Rothbergin a technology-based incubator called 4Catalyzer,Hyperfine, Inc.scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visithyperfine.io.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks ofHyperfine, Inc.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results ofHyperfine, Inc.(the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with theSecurities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241001092541/en/

Media ContactDana SchroederHealth+Commercedana@healthandcommerce.comInvestor ContactMarissa BychGilmartin Group LLCmarissa@gilmartinir.com

Source:Hyperfine, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com